NPCE
NeuroPace, Inc. (NASDAQ)
Healthcare — Medical Devices
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Price History
Fundamentals
| Market Cap | $537.66M |
| P/E Ratio (TTM) | - |
| Forward P/E | -53.05 |
| EPS (TTM) | $-0.65 |
| Dividend Yield | - |
| Profit Margin | -21.67% |
| Revenue Growth | -2.00% |
| ROE | -111.38% |
| Debt/Equity | 487.49 |
| Recommendation | None |
| Analyst Target | $20.00 |
| Analysts | 8 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 50.8 |
| Beta | 1.88 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $19.60 |
| 52-Week Low | $7.56 |
| 50-Day Avg | $16.36 |
| 200-Day Avg | $14.53 |
| Avg Volume | 183.8K |
| Volume | 187.6K |
Performance Analysis
NEUTRALNPCE presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:23 UTC
Back to Screener Export Report